Travere Therapeutics has delivered 56% revenue growth and three consecutive earnings beats with an average surprise above 300%, driven by its FILSPARI product, but the stock has exceeded analyst targets, carries 20% short interest, and is burning cash at negative 10% of revenue.
Thesis pillars
- Filspari Revenue Growth→Stable
- Product Supplier Concentration↓Deteriorating
- Cash Burn Rate→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026
Travere Therapeutics, Inc. (TVTX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $50.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.83; Below-average business quality.
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FILSPARI (sparsentan) receiving full FDA approval in September 2024 as the first non-immunosuppressive therapy for IgA nephropathy. Revenue is generated from U.S. sales of... Read more
Sell if holding. Engine safety override at $50.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.83; Below-average business quality. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 6.1/10, moderate confidence.
Passes 3/7 gates (favorable risk/reward ratio, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and earnings proximity 4d<=7d. Suitability: speculative.
About Travere Therapeutics, Inc.
About Travere Therapeutics, Inc.
FILSPARI (sparsentan) received full FDA approval in September 2024 as the first and only approved oral, once-daily, non-immunosuppressive therapy indicated to slow kidney function decline in adults with primary IgA nephropathy. Travere Therapeutics simultaneously has an sNDA under FDA review for FILSPARI in focal segmental glomerulosclerosis, with a PDUFA target action date of April 13, 2026. Revenue is supplemented by milestone payments, including a $17.5 million regulatory milestone from CSL Vifor in May 2025 and a $40.0 million market access milestone in Q4 2025.
Travere earns product revenue primarily from U.S. sales of FILSPARI for IgAN and Thiola (tiopronin) for cystinuria, distributed through third-party distributors as the company has no in-house distribution capabilities. Manufacturing of both commercialized products is contracted exclusively to third-party sole-source suppliers, since Travere has no manufacturing capabilities. Ex-U.S. commercialization of sparsentan is delegated entirely to CSL Vifor — covering Europe, Australia, and New Zealand — and to Chugai, which acquired Renalys in Q4 2025 and assumed Japan, South Korea, and Taiwan rights. Thiola faces generic competition following FDA approval of generic tiopronin tablets in 2021 and 2022, which has pressured revenue from that product line. Pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU), is in a pivotal Phase 3 HARMONY Study that restarted enrollment in Q1 2026 after a voluntary pause related to manufacturing scale-up challenges.
Show full overview
The FSGS indication represents the highest-binary-event risk in Travere's portfolio. The Phase 3 DUPLEX Study did not achieve its two-year primary eGFR endpoint with statistical significance over irbesartan; the sNDA submitted in March 2025 relied on proteinuria-based evidence supported by the independent PARASOL workgroup. In January 2026, the FDA extended the review timeline after Travere submitted additional responses — classified as a Major Amendment — pushing the PDUFA date from January 13 to April 13, 2026. A complete response letter from the FDA would delay and potentially extinguish the FSGS expansion opportunity, leaving the company dependent on IgAN revenues and milestone timing from its licensing partners.
See also: Healthcare · Biotechnology
From Travere Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-10-29Recent Developments — Travere Therapeutics, Inc.
Latest news
- NEWS Travere Therapeutics to Report Third Quarter 2026 Financial Results — fiscal.ai Oct 27, 2026
- NEWS Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decli — benzinga Oct 26, 2026 positive
- NEWS Travere Therapeutics Presents New Biomarker Data for FILSPARI at ASN Kidney Week 2026 — fiscal.ai Oct 24, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Oct 23, 2026 neutral
- NEWS FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades — benzinga Oct 13, 2026 negative
Generated 2026-10-29T10:28:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductFILSPARI10-K Item 1A: 'generate significant product revenues...will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan)'
- HIGHSuppliersole source manufacturers (FILSPARI and Thiola)10-K Item 1A: 'rely on third-party manufacturers who are currently sole source suppliers for manufacturing of FILSPARI and Thiola'
- MEDIUMpipelinesparsentan FSGS sNDA10-K Item 1: 'If approved, FILSPARI could become the first and only FDA-approved medicine indicated for FSGS'
- MEDIUMpipelinepegtibatinase Phase 3 HARMONY10-K Item 1: 'We are conducting a pivotal Phase 3 study to support the potential approval of pegtibatinase as the first disease modifying therapy for HCU'
Material Events(8-K, last 90d)
- 2026-05-21Item 5.02LOWAt the May 19, 2026 Annual Meeting, Travere Therapeutics shareholders approved an amendment to the 2018 Equity Incentive Plan increasing authorized shares by 3,000,000. No director or officer departure cited; the 5.02 item relates to a compensatory arrangement approval.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Risk profile below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $50.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 6.1/10 and A.R:R 3.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.83; Below-average business quality. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $47.76. Score 6.1/10, moderate confidence.
Analyst target: $65.44 (+28.7% upside). Prior stop was $47.76. Stop-loss: $47.76.
Concentration risk — Product: FILSPARI; Concentration risk — Supplier: sole source manufacturers (FILSPARI and Thiola); Quality below floor (3.8 < 4.0).
Travere Therapeutics, Inc. trades at a P/E of N/A (forward 9.4). TrendMatrix value score: 7.6/10. Verdict: Sell.
21 analysts cover TVTX with a consensus score of 4.3/5. Average price target: $75.
What does Travere Therapeutics, Inc. do?Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FILSPARI...
Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases, with FILSPARI (sparsentan) receiving full FDA approval in September 2024 as the first non-immunosuppressive therapy for IgA nephropathy. Revenue is generated from U.S. sales of FILSPARI and Thiola, plus milestones from ex-U.S. licensees CSL Vifor and Chugai. Manufacturing is outsourced entirely to third-party sole-source suppliers.